Skip to content

The Canadian preterm labour nitroglycerin trial

Transdermal nitroglycerin to reduce the incidence of neonatal mortality in women who present in preterm labour: a placebo-controlled randomised trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN20129681
Enrollment
600
Registered
2005-09-26
Start date
2001-05-04
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm labour Pregnancy and Childbirth Preterm labour

Interventions

Patients receive a intravenous bolus of saline (500 - 1000 ml) prior to randomisation. They have 1 study patch (drug or placebo) placed and a second additional patch placed after one hour if ongoing u

Sponsors

Queen's University (Canada)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Greater than or equal to 24 to less than or equal to 32 weeks gestational age based on menstrual dates or earliest ultrasound scan 2. Preterm labour: 2.1. At least four painful uterine contractions per 20 minutes 2.2. Change in the cervix (change in bishop score or bishop score greater than or equal to 6)

Exclusion criteria

Exclusion criteria: 1. Any maternal (e.g. significant antepartum haemorrhage) or foetal (e.g. non-reassuring heart rate pattern) condition necessitating immediate delivery 2. Multiple gestations (i.e. twins, triplets etc.) 3. Premature prelabour rupture of the membranes (PPROM) 4. Intrauterine foetal demise or lethal foetal anomalies 5. Cervix dilated greater than 8 cm 6. Treatment with another agent within 24 hours 7. Previous enrolment in this trial 8. Known sensitivity to GTN 9. Failure to give consent

Design outcomes

Primary

MeasureTime frame
Neonatal morbidity and prenatal mortality

Secondary

MeasureTime frame
1. Randomisation to delivery interval 2. Incidence of preterm delivery less than 48 hours after initiation of treatment 3. Incidence of delivery within 7 days of commencement of treatment 4. Incidence of delivery prior to 34 weeks gestation 5. Frequency of chorioamnionitis in preterm delivery 6. Frequency of completed course of antenatal corticosteroids 7. Frequency of side effects

Countries

Canada

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026